What's behind GSK's latest 1.5% stock pullback?

Traders Union
All News
Stocks
Gsk slides 1.5% today to GBX1804

Highlights

GSK plc reported third-quarter 2026 sales growth of 5% at constant exchange rates to £8.9 billion, led by specialty medicines in respiratory disease and oncology.
The company maintained its 2026 core earnings per share growth guidance at 7 to 9% and declared a third-quarter dividend of 17 pence per share.
Shares of GSK traded below key moving averages with selling pressure and high probability of staying in the GBX1,732 to GBX1,875 range over five days.

Specialty medicines growth offsets vaccine slump amid persistent selling

GSK plc reported its third-quarter 2026 earnings, showing 5% sales growth at constant exchange rates to £8.9 billion, with specialty medicines driving performance through new launches in respiratory disease and oncology. Core earnings per share growth guidance for 2026 was maintained at 7–9%, and the company declared a third-quarter dividend of 17 pence per share, targeting 70 pence for the full year. Free cash flow rose by £1.8 billion year to date, supported by the out-licensing of linerixibat and a special dividend from changes in ViiV Healthcare shareholding, and vaccine sales declined 2% mainly due to a 24% drop in Arexvy. Twenty-two phase III trials remain on track for 2026, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, identifies persistent technical weakness in GSK plc, with the stock under all primary moving averages and sellers dictating momentum. He highlights the limited impact of steady sales growth and guidance reaffirmation as sentiment remains pressured by falling vaccine sales and reliance on out-licensing deals for cash flow. Kharitonov notes that mixed momentum signals—especially weak RSI and Stochastic RSI—point to ongoing uncertainty rather than recovery. He doubts the strength of recent earnings drivers, seeing fundamentals as insufficient to overcome structural bearishness. "Until price breaks above a meaningful resistance or delivers a catalyst beyond guidance and asset disposals, I remain highly cautious on the upside potential for GSK," Kharitonov concludes.

Viktoras Karapetjanc, expert at Traders Union, emphasizes GSK's resilience despite a short-term price correction. He points to robust 5% sales growth at constant exchange rates, stable earnings guidance, and meaningful dividend delivery as strong fundamental supports. Karapetjanc sees recent specialty medicine launches and cash flow improvements as positive drivers for long-term positioning. He believes the baseline scenario favors ongoing consolidation with opportunities ahead, particularly given the advancing phase III pipeline. "In my view, the bullish structure remains intact, and I expect further growth once market dynamics turn more favorable for GSK," says Karapetjanc.

Parshwa Turakhiya, analyst, observes GSK's price action in a tight, sentiment-driven range. He notes intraday bullish attempts stalling near the GBX1,817 resistance, while neutral-to-bearish oscillators keep traders defensive. Turakhiya highlights the divergence among momentum indicators as a signal for tactical rather than directional setups. He sees short-term volatility bands as a possible opportunity for nimble trades around the forecast corridor. "If price breaks either side of this current sideways channel, I would look to quickly follow momentum for a short-term move," Turakhiya advises.

Mixed momentum and resistance challenge as technical signals diverge

GSK stock is trading below its 20-day (GBX1,826), 50-day (GBX1,849), and 200-day (GBX1,951) moving averages, confirming ongoing pressure from sellers across short-, medium-, and long-term horizons. The Ichimoku Kijun at GBX1,832 acts as resistance, with the price currently trading between the near-term floor at GBX1,790 and ceiling at GBX1,817. The longer-term trend bias remains bearish given the MA-50 vs MA-200 alignment. Momentum readings are mixed. MACD signals a buy and ADX is neutral, but the Relative Strength Index (RSI) at 47.25 generates a sell forecast, and Stochastic RSI at 38.03 points to strong sell conditions. The Commodity Channel Index (CCI) is neutral, and Bull/Bear Power (BBP) indicates buyers still dominate intraday momentum, yet its overbought warning suggests caution. Multiple oscillators and momentum indicators diverge, highlighting uncertainty as the session develops.

Earlier, analysts noted that GSK faced prevailing downside risks, with technical and fundamental signals highlighting bearish momentum. The latest price action reinforces this negative bias, and traders should watch for a convincing move above GBX1,832 resistance or a drop below the GBX1,790 floor as signals for the stock's next directional move.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.